AUTHORS
Geoffrey L. Uy, MD, Ramzi Abboud, MD2, Samuel Urrutia, MD, MS3, Meagan A. Jacoby, MD, PhD4, Zachary D. Crees, MD5, Iskra Pusic, MD MSCI6, Matthew J. Christopher, MD, PhD7, Sharon Heath8, Giulia Petrone, MD9, John F. DiPersio, MD10, Haley Abel, PhD11, Andrew E.O. Hughes, MD, PhD12, Francesca Ferraro, MD,PhD13, Eric Duncavage, MD14, David H Spencer, MD, PhD15
AFFILIATIONS
1 Washington University School of Medicine, Saint Louis, Missouri, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Washington University School of Medicine, Saint Louis, Missouri, United States
4 Washington University School of Medicine, Saint Louis, Missouri, United States
5 Washington University School of Medicine, Saint Louis, Missouri, United States
6 Washington University School of Medicine, Saint Louis, Missouri, United States
7 Washington University School of Medicine, Saint Louis, Missouri, United States
8 Washington University School of Medicine, Saint Louis, Missouri, United States
9 Washington University School of Medicine, Saint Louis, Missouri, United States
10 Washington University School of Medicine, Saint Louis, Missouri, United States
11 Washington University School of Medicine, Saint Louis, Missouri, United States
12 Washington University School of Medicine, Saint Louis, Missouri, United States
13 Washington University School of Medicine, Saint Louis, Missouri, United States
14 Washington University School of Medicine, Saint Louis, Missouri, United States, Washington University School of Medicine, Saint Louis, Missouri, United States
15 Washington University School of Medicine, Saint Louis, Missouri, United States
ABSTRACT
Background: Partial tandem duplications (PTD) of KMT2A are recurring genetic abnormalities in patients with AML and MDS that have been associated with an adverse prognosis. Most standard approaches for molecular profiling fail to identify KMT2A-PTD as they cannot be easily detected by conventional cytogenetics, FISH, or panel-based DNA sequencing. Our previous work (Duncavage et al., NEJM 2021) validated whole-genome sequencing (WGS) as a single platform to provide rapid, comprehensive genomic analysis of patients with myeloid malignancies and can more readily detect alterations like KMT2A-PTD. Here, we sought to characterize the genomic and clinical characteristics of patients with myeloid malignancies harboring cryptic KMT2A-PTD identified by WGS.
Methods: We performed WGS on 1007 bone marrow or peripheral blood samples from 924 unique patients who were evaluated at Washington University School of Medicine for a known or suspected acute leukemia and consented for genomic studies. WGS was performed to a target depth of >60x, and analysis was performed with DRAGEN v4.4 with parameters for hematologic malignancies, followed by custom variant filtering and prioritization for mutations in 65 recurrently mutated genes and structural variants affecting 646 genes. Duplication events involving KMT2A that did not extend beyond the gene boundaries were identified as PTD.
Results: We identified 41 patients (4.4%) with a KMT2A-PTD by whole-genome sequencing. The median age of the cohort was 62 years (range 25-84) with a diagnosis of AML (n=27), MDS (n=10), or MDS/MPN including CMML (n=4). The KMT2A-PTD most frequently consisted of a duplication in exons 2-10 (n=19, 46%) or exons 2-8 (n=17, 41%). The most common co-mutated genes were DNMT3A (n=18, 44%), FLT3 (n=16, 39%), TET2 (n=13, 32%), RUNX1 (n=12, 29%), and STAG2 (n=12, 29%). Overall, 32 out of 41patients (80%) had a mutation in either TP53 (n=2, 5%) or at least one MDS-related gene (n=30, 73%). Thirteen (32%) of patients had MDS-related defining structural abnormalities, and 22 (54%) had a normal karyotype. Of the 27 patients with AML, eight were classified as ELN 2022 intermediate risk and 19 were adverse risk. The initial treatment of patients with AML consisted of intensive chemotherapy with cytarabine plus an anthracycline-based regimen (7+3 or CPX-351, n =21, 78%) or a hypomethylating agent +/- venetoclax (n=6, 22%).
For the entire cohort, the median overall survival (OS) was 11.86 months (95% CI, 7.23-18.86) with a 3-year OS of 18.8%. For the AML cohort, the median OS was 14.95 months (95% CI, 3.84-24). Notably for patients with AML who did not undergo alloHCT (n=17), the median OS was a dismal 4.0 months (95% CI, 2.0-15.0) with a 1 yr OS of 15% compared to patients (n=11) who did undergo alloHCT with a median OS of 93.3 months (95% CI, 14.95-NR) and a 1-year OS of 89%.
Conclusions: KMT2A-PTD represent a common, underrecognized genetic abnormality in patients with myeloid malignancies that frequently co-occur with MDS-associated gene mutations. In patients with AML, the presence of a KMT2A-PTD carries a dismal prognosis in the absence of an alloHCT. These data suggest that KMT2A-PTD are clinically relevant and potentially actionable genetic abnormality and strongly support the use of platforms such as WGS that can detect KMT2A-PTD as part of the initial evaluation of patients with myeloid malignancies.
DISCLOSURES
Geoffrey L. Uy, MD: Geron - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Vironexis - Consultancy (Includes expert testimony)